The Wisdom of Snowden

As I Found Out With My Daughter, Not Even Catholic Schools Are Safe Havens From Gender Ideology

Our daughter, now 15, was 13 when she was coached into believing that she was born in the wrong body and could change to be the opposite sex. This led her to self-loathing.

But instead of finding a partner within the Roman Catholic Church, we discovered that our local Catholic high school had adopted procedures that promote transgenderism. This situation has left us with no safe place to educate our child and a profound feeling of disappointment and abandonment.

Everything Is Now Russian Disinformation

The U.S. government would like to inform you that Western civilization is not, in fact, collapsing. If you’ve ever suspected otherwise, if you’ve looked around and noticed widespread signs of material and cultural decay, you should seek a narrative reset immediately. Because chances are, you’ve fallen victim to a false narrative injected by the Kremlin’s “disinformation and propaganda ecosystem…into the global information environment.”

Data scientist DESTROYS the BLM narrative

Zac Kriegman has a bachelor’s in economics from Michigan and a J.D. from Harvard and years of experience with high-tech startups, a white-shoe law firm, and an econometrics research consultancy. He then spent six years at Thomson Reuters Corporation, the international media conglomerate, spearheading the company’s efforts on artificial intelligence, machine learning, and advanced software engineering. By the beginning of 2020, Kriegman had assumed the title of Director of Data Science and was leading a team tasked with implementing deep learning throughout the organization.

BMJ Demands Covid Vaccine Accountability

Pfizer’s pivotal covid vaccine trial was funded by the company and designed, run, analysed, and authored by Pfizer employees. The company and the contract research organisations that carried out the trial hold all the data.17 And Pfizer has indicated that it will not begin entertaining requests for trial data until May 2025, 24 months after the primary study completion date, which is listed on as 15 May 2023 (NCT04368728).

The lack of access to data is consistent across vaccine manufacturers.16 Moderna says data “may be available … with publication of the final study results in 2022.”18 Datasets will be available “upon request and subject to review once the trial is complete,” which has an estimated primary completion date of 27 October 2022 (NCT04470427).

As of 31 December 2021, AstraZeneca may be ready to entertain requests for data from several of its large phase III trials.19 But actually obtaining data could be slow going. As its website explains, “timelines vary per request and can take up to a year upon full submission of the request.”20

Underlying data for covid-19 therapeutics are similarly hard to find. Published reports of Regeneron’s phase III trial of its monoclonal antibody therapy REGEN-COV flatly state that participant level data will not be made available to others.21 Should the drug be approved (and not just emergency authorised), sharing “will be considered.” For remdesivir, the US National Institutes of Health, which funded the trial, created a new portal to share data (, but the dataset on offer is limited. An accompanying document explains: “The longitudinal data set only contains a small subset of the protocol and statistical analysis plan objectives.”

We are left with publications but no access to the underlying data on reasonable request. This is worrying for trial participants, researchers, clinicians, journal editors, policy makers, and the public. The journals that have published these primary studies may argue that they faced an awkward dilemma, caught between making the summary findings available quickly and upholding the best ethical values that support timely access to underlying data. In our view, there is no dilemma; the anonymised individual participant data from clinical trials must be made available for independent scrutiny.